Compare AstraZeneca plc (AZN) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Monster Beverage Corp — how do they compare? AstraZeneca plc trades at $167.12 (market cap $253.13B), while Monster Beverage Corp trades at $98.03 (market cap $95.85B). The key difference: AstraZeneca plc is far larger — about 2.6× Monster Beverage Corp's market cap, and AstraZeneca plc pays a 1.92% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| AZN | MNST | |
|---|---|---|
Market Cap | $253.13B | $95.85B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $98.01 |
52-Week Low | $137.44 | $58.65 |
Enterprise Value | $279.37B | $94.15B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Monster Beverage (MNST) trades at $97.07, down 0.33% on the day, with strong technical bullish signals from moving averages and a neutral RSI. The company demonstrates robust fundamentals with 2025 revenue of $8.29B, net income of $1.91B, and consistent earnings beats. Recent corporate actions include a 2-for-1 stock split effective August 11, 2026, reflecting management confidence in continued growth prospects.
MNST presents a compelling growth story with accelerating international expansion and product innovation driving market share gains. However, premium valuation multiples (P/E 46.89, P/S 10.89) create vulnerability to earnings disappointments. Analyst consensus remains positive with 53% buy ratings, though the $94.60 price target suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
